Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference

Catabasis Pharmaceuticals, Inc. CATB, a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide a business update at the upcoming Solebury Trout Virtual Investor Conference on Tuesday, March 31, 2020 at 12:30pm EDT.

A webcast of the presentation will be available in the investors section of the Company's website www.catabasis.com, and will be archived for 30 days following the presentation.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005033/en/